Miro clears TGA audit ahead of Crohn’s disease trial
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
4 reports · 4 sources
The AgeMiro clears TGA audit ahead of Crohn’s disease trialSydney Morning HeraldMiro clears TGA audit ahead of Crohn’s disease trialSydney Morning HeraldMiro clears TGA audit ahead of Crohn’s disease trialThe AgeMiro clears TGA audit ahead of Crohn’s disease trial10 recorded states
Signal first indexedP1 · 68% quality · 1 source
Corroboration 1→2 sources · quality 68→72P1 · 72% quality · 2 sources
Quality 72→76P1 · 76% quality · 2 sources
Quality 76→80P1 · 80% quality · 2 sources
Quality 80→84P1 · 84% quality · 2 sources
Quality 84→88P1 · 88% quality · 2 sources
Quality 88→92P1 · 92% quality · 2 sources
Quality 92→96P1 · 96% quality · 2 sources
Corroboration 2→3 sources · quality 96→99P1 · 99% quality · 3 sources
Corroboration 3→4 sourcesP1 · 99% quality · 4 sources